AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. Technological advances have greatly increased the life span for CF patients. While children with CF rarely made it to elementary school age in the 1950s, the median age of survival for a CF patient is now around 47 years, with many patients living into their 60s (https://ibn.fm/RQcG4). A recent article discusses AZRX’s positioning amid the work in targeted treatments. It reads, “Due to the efforts of companies such as AzurRx BioPharma, the life span and quality of life of CF patients could be further improved. AzurRx’s lead product is MS1819, a recombinant lipase that could potentially change the treatment of exocrine pancreatic insufficiency in CF and CP patients.”
To view the full article, visit https://ibn.fm/SSZtf
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
